首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1439242

神經調節設備 - 全球市場考量、競爭格局、市場預測 (2030)

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

全球神經調節設備市場規模預計到 2023 年將達到 57.1 億美元，到 2030 年將達到 95.6 億美元，2024-2030 年預測期間複合年增長率為 8.95%。對神經調節設備的需求主要由老年人口的增長和神經系統疾病患病率的增加、設備擴展到其他慢性適應症和目標用途、產品組合的技術進步以及患者對神經系統疾病的需求不斷增加所推動。部分原因是政府加大力度提高意識。

神經調節設備市場動態

神經系統疾病是主要影響中樞和周邊神經系統的疾病，包括腦、脊髓、腦神經、週邊神經、神經根、自主神經系統、神經肌肉接頭和肌肉。根據世界衛生組織（WHO）2023年提供的數據，全球約有5,000萬人患有癲癇症，使其成為2019年全球最常見的神經系統疾病之一。大約 80% 的癲癇患者生活在低收入和中等收入國家。

根據世界衛生組織2023年發布的數據，約有5,500萬人患有失智症，每年新增病例近1,000萬例。

神經調節是一種直接影響神經的技術。它透過直接向目標區域施加電刺激來改變（或調節）神經活動。神經調節裝置將電極連接到大腦、脊髓和周邊神經，以治療和緩解各種神經系統疾病的症狀，例如癲癇、偏頭痛和帕金森氏症。因此，全球各種神經系統疾病的日益普及可能成為全球神經調節設備市場的成長動力。

此外，神經調節裝置幾乎可以治療任何疾病或病症，從頭痛到震顫、脊髓損傷、尿失禁等。憑藉如此廣泛的治療範圍和生物技術的持續重大改進，神經調節在預測期內被定位為高成長產業也就不足為奇了。除了慢性疼痛治療之外，神經調節還有許多應用，包括帕金森氏症的深部腦部刺激（DBS）療法、針對骨盆腔疾病和尿失禁的薦神經刺激療法。例如，Medtronic的ENTERRA II NEUROSTIMULATOR是一種胃神經刺激裝置，可產生微弱的電脈衝，用於電刺激胃，以治療胃輕癱引起的慢性、頑固性噁心和嘔吐。

因此，擴大用於其他慢性適應症和目標應用的設備的使用預計也將推動全球神經調節設備市場。

然而，這些設備的高成本以及低診斷和治療率等某些因素可能會限制神經調節設備市場的成長。

神經調節設備市場細分分析

在神經調節設備產品領域，脊髓刺激設備在預測期內將佔據很大的市場。這是由於患有慢性疼痛、脊椎手術後疼痛症候群和複雜區域疼痛症候群 (CRPS) 的患者數量不斷增加。例如，根據CDC（2020）的數據，2019年，20.4%的成年人患有慢性疼痛，7.4%的成年人患有經常限制其生活和工作活動的慢性疼痛（稱為高負擔慢性疼痛） . ，兩者都隨著年齡的增長而增加，並且在65 歲及以上的成年人中最高。

此外，最近推出的技術先進的脊髓刺激設備（配有可充電電池和無線遠端技術）的產品也促進了該領域的成長。例如，Boston Scientific Corporation於 2020 年在歐洲推出了脊髓刺激設備 (SCS) 系統的 WaveWriter Alpha□ 產品組合。該產品組合由四個支援MRI 條件的藍牙植入式脈衝產生器(IPG) 組成，可提供患者友好型選項，包括可充電和不可充電選項以及可覆蓋多個疼痛區域的波形。我們正在基於以下基礎擴展個性化範圍：需要。

該報告提供了全球神經調節設備市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

神經調節設備市場的驅動因素
- 老年人口增加及神經系統疾病盛行率增加
- 該設備擴展到其他慢性疾病和針對性應用
- 我們產品組合的技術進步
- 政府加強提高患者對神經系統疾病的認識
神經調節設備市場的限制與挑戰
- 設備和程序成本高
- 複雜的監管審批場景
神經調節設備的市場機會
- 對非侵入式設備的需求不斷增長
- 發展中國家的市場成長機會

第5章神經調節裝置的波特五力分析

第6章神經調節設備市場佈局

按類型
- 侵入性的
- 非侵入性
按產品類型
- 脊髓刺激裝置
- 迷走神經刺激裝置
- 腦深部電刺激裝置
- 薦神經刺激裝置
- 經顱磁刺激儀
- 其他
按用途
- 疼痛管理
- 神經系統疾病
- 呼吸系統疾病
按最終用戶
- 醫院
- 專科診所
按地區
- 北美
- 歐洲神經調節設備市場規模（2021-2030）
- 亞太地區神經調節設備市場規模（2021-2030）
- 其他地區神經調節設備市場規模（2021-2030）

第7章神經調節設備公司及產品簡介

Medtronic
Boston Scientific Corporation
Abbott
LivaNova
NeuroSigma
NEVRO CORP.
Synapse Biomedical Inc.
NeuroPace, Inc.
Bioventus
Soterix Medical Inc.
Helius Medical Technologies
Axonics, Inc.
MicroTransponder Inc.
electroCore, Inc.

第8章 KOL觀點

第9章專案方法

第10章 DelveInsight服務內容

第11章關於 DelveInsight

第12章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0029

Neuromodulation Devices Market By Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography is expected to grow at a static CAGR forecast till 2030 due to Advances in Product Portfolio and Burgeoning Neurological Disorder Prevalence among the aging population

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily motivated by the increasing prevalence of neurological disorders coupled with the rising aging population, expansion of the devices to other chronic indications and target applications, technological advancement in the product portfolio, rising government initiatives to raise awareness among patient regarding neurological disorders, among others.

Neuromodulation Devices Market Dynamics:

Neurological disorders are diseases that affect the central and peripheral nervous system which primarily include the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. According to the data provided by the World Health Organization (WHO) 2023, approximately 50 million people across the globe were suffering from epilepsy, making it one of the most common neurological diseases globally in 2019. About 80% of people with epilepsy live in low- and middle-income countries.

As per the data provided by WHO 2023, about 55 million people are living with dementia, and there are nearly 10 million new cases every year.

Neuromodulation is a technique that directly acts on nerves. It changes (or modulates) nerve activity by delivering electrical stimulation directly to the target area. Neuromodulation devices involve applying electrodes to the brain, spinal cord, or peripheral nerves to treat or reduce the symptom of various neurological disorders such as epilepsy, migraine, and Parkinson's disease, among others. Therefore the rising prevalence of various neurological disorders across the globe could be a potential factor leading to the growth of the global neuromodulation devices market.

Moreover, neuromodulation devices treat almost all diseases or symptoms, from headaches to tremors, spinal cord injuries and urinary incontinence, and others. With such a wide range of treatments and significant continuous improvements in biotechnology, it is not surprising that neuromodulation is positioned as a high-growth industry during the forecasted period. In addition to treating chronic pain, there are many neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic diseases, and urinary incontinence. For instance, ENTERRA II NEUROSTIMULATOR by Medtronic is a gastric neurostimulator that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.

Therefore, the expansion of device usage to other chronic indications and targeted applications is also anticipated to propel the global neuromodulation devices market.

However, certain factors such as the high cost of these devices and the lower rate of diagnosis and treatment are likely to impede the growth of the neuromodulation devices market.

Neuromodulation Devices Market Segment Analysis:

Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the neuromodulation devices product segment, spinal cord stimulators hold a significant market during the forecasted period. This is owing to the growing patient population suffering from chronic pain, failed back syndrome, and complex regional pain syndrome (CRPS). For instance, according to CDC 2020 data, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high-impact chronic pain) and both increased with age and were highest among adults aged 65 and over.

Moreover, recent product launches of technologically advanced spinal cord stimulators with rechargeable batteries and wireless remote techniques also contribute to segmental growth. For instance, in 2020, Boston Scientific Corporation launched the WaveWriter Alpha(TM) portfolio of Spinal Cord Stimulator (SCS) Systems in Europe. The portfolio consists of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), that offer expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.

In addition, emerging guidelines from the government for spinal cord stimulation therapy for the treatment of chronic pain and other indications are also anticipated to augment the market. For instance, in January 2019, National Institute for Health and Care Excellence (NICE) published guidelines and recommendations for Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

Hence, all the mentioned factors are likely to fuel the segmental growth of the Neuromodulation Devices market during the forecasted period.

North America is expected to dominate the overall Neuromodulation Devices Market:

North America is expected to dominate the overall Neuromodulation Devices market during the forecast period. This domination is due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Moreover, higher diagnosis and treatment rates and adequate reimbursement policies are the driving factors.

Further, In the United States, the presence of neuromodulation device companies in the market such as Abbott, Boston Scientific Corporation, and Medtronic, among others is likely to boost the market. Also, the growing prevalence of neurological disorders such as Parkinson's disease, epilepsy, migraine, and treatment-resistant depressive order is expected to bolster the market. For instance, as per the Parkinson's Foundation 2022 study, every year in the United States about 90,000 people are diagnosed with Parkinson's disease. Thus, rising cases of Parkinson's among other neurological disorders could be a significant factor for the neuromodulation devices market growth.

Moreover, an increase in product approval by FDA is also a driving factor for neuromodulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept(TM) PC Deep Brain Stimulation (DBS) system. BrainSense(TM) technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy, or obsessive-compulsive disorder (OCD).

Thus, the aforementioned factors are likely to upsurge the market for neuromodulation devices in the region.

Neuromodulation Devices Market Key Players:

Some of the key market players operating in the neuromodulation devices market include Medtronic,

Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others.

Recent Developmental Activities in Neuromodulation Devices Market:

In March 2021, Axonics Modulation Technologies, Inc. entered into a strategic alliance with Micro Systems Technologies (MST) for the manufacture of a non-rechargeable implantable sacral neuromodulation device.

In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.

In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.

Key Takes Away from the Neuromodulation Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global neuromodulation devices market.

Various opportunities available for the other competitor in the neuromodulation devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for neuromodulation devices market growth in the coming future?

Target Audience who can be benefited from Neuromodulation Devices Market Report Study

Neuromodulation Devices providers

Research organizations and consulting companies

Neuromodulation Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Neuromodulation Devices

Various End-Users who want to know more about the neuromodulation devices market and the latest technological developments in the neuromodulation devices market.

Frequently Asked Questions for Neuromodulation Devices Market:

1. What are neuromodulation devices?

Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.

2. What is the market for global neuromodulation devices?

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030.

3. What are the drivers for global neuromodulation devices?

The major factors driving the demand for neuromodulation devices are the growing prevalence of neurological disorders coupled with the rising geriatric population, expanding device application in various other indications, and the launch of technically advanced products in the market.

4. What are the key players operating in global neuromodulation devices?

Some of the key market players operating in the neuromodulation devices market include Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others

5. Which region has the highest share in the neuromodulation devices market?

North America is anticipated to dominate the overall Neuromodulation Devices market during the forecast period, 2024-2030 due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Furthermore, rising diagnosis and treatment rates and adequate reimbursement policies also contribute to the highest regional share.

1. Neuromodulation Devices Report Introduction

2. Neuromodulation Devices Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Neuromodulation Devices Market Key Factors Analysis

4.1. Neuromodulation Devices Market Drivers
- 4.1.1. Increasing prevalence of neurological disorder coupled with a rising aging population
- 4.1.2. Expansion of the devices to other chronic indications and target application
- 4.1.3. Technological advancement in the product portfolio
- 4.1.4. Rising government initiative to raise awareness among patients regarding neurological disorders
4.2. Neuromodulation Devices Market Restraints and Challenges
- 4.2.1. High cost of the devices and procedure
- 4.2.2. Complex regulatory approval scenario
4.3. Neuromodulation Devices Market Opportunities
- 4.3.1. Growing demand for non-invasive devices
- 4.3.2. Market growth opportunities in developing nations

5. Neuromodulation Devices Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. Neuromodulation Devices Market layout

6.1. By Type
- 6.1.1. Invasive
- 6.1.2. Non-invasive
6.2. By Product Type
- 6.2.1. Spinal Cord Stimulators
- 6.2.2. Vagus Nerve Stimulators
- 6.2.3. Deep Brain Stimulators
- 6.2.4. Sacral Nerve Stimulators
- 6.2.5. Transcranial Magnetic Stimulators
- 6.2.6. Others
6.3. By Application
- 6.3.1. Pain Management
- 6.3.2. Neurological disorder
- 6.3.3. Respiratory disorder
- 6.3.4. Others
6.4. By End-User
- 6.4.1. Hospitals
- 6.4.2. Specialty Clinics
- 6.4.3. Others
6.5. By Geography
- 6.5.1. North America
  - 6.5.1.1. United States Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.1.2. Canada Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.1.3. Mexico Neuromodulation Devices Market Size in USD million (2021-2030)
- 6.5.2. Europe Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.1. France Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.2. Germany Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.3. United Kingdom Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.4. Italy Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.5. Spain Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.2.6. Rest of Europe Neuromodulation Devices Market Size in USD million (2021-2030)
- 6.5.3. Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.1. China Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.2. Japan Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.3. India Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.4. Australia Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.5. South Korea Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.3.6. Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
- 6.5.4. Rest of the World (RoW) Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.4.1. Middle East Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.4.2. Africa Neuromodulation Devices Market Size in USD million (2021-2030)
  - 6.5.4.3. South America Neuromodulation Devices Market Size in USD million (2021-2030)

7. Neuromodulation Devices Company and Product Profiles

7.1. Medtronic
- 7.1.1. Company Overview
- 7.1.2. Company Snapshot
- 7.1.3. Financial Overview
- 7.1.4. Product Listing
- 7.1.5. Entropy
7.2. Boston Scientific Corporation
- 7.2.1. Company Overview
- 7.2.2. Company Snapshot
- 7.2.3. Financial Overview
- 7.2.4. Product Listing
- 7.2.5. Entropy
7.3. Abbott
- 7.3.1. Company Overview
- 7.3.2. Company Snapshot
- 7.3.3. Financial Overview
- 7.3.4. Product Listing
- 7.3.5. Entropy
7.4. LivaNova
- 7.4.1. Company Overview
- 7.4.2. Company Snapshot
- 7.4.3. Financial Overview
- 7.4.4. Product Listing
- 7.4.5. Entropy
7.5. NeuroSigma
- 7.5.1. Company Overview
- 7.5.2. Company Snapshot
- 7.5.3. Financial Overview
- 7.5.4. Product Listing
- 7.5.5. Entropy
7.6. NEVRO CORP.
- 7.6.1. Company Overview
- 7.6.2. Company Snapshot
- 7.6.3. Financial Overview
- 7.6.4. Product Listing
- 7.6.5. Entropy
7.7. Synapse Biomedical Inc.
- 7.7.1. Company Overview
- 7.7.2. Company Snapshot
- 7.7.3. Financial Overview
- 7.7.4. Product Listing
- 7.7.5. Entropy
7.8. NeuroPace, Inc.
- 7.8.1. Company Overview
- 7.8.2. Company Snapshot
- 7.8.3. Financial Overview
- 7.8.4. Product Listing
- 7.8.5. Entropy
7.9. Bioventus
- 7.9.1. Company Overview
- 7.9.2. Company Snapshot
- 7.9.3. Financial Overview
- 7.9.4. Product Listing
- 7.9.5. Entropy
7.10. Soterix Medical Inc.
- 7.10.1. Company Overview
- 7.10.2. Company Snapshot
- 7.10.3. Financial Overview
- 7.10.4. Product Listing
- 7.10.5. Entropy
7.11. Helius Medical Technologies
- 7.11.1. Company Overview
- 7.11.2. Company Snapshot
- 7.11.3. Financial Overview
- 7.11.4. Product Listing
- 7.11.5. Entropy
7.12. Axonics, Inc.
- 7.12.1. Company Overview
- 7.12.2. Company Snapshot
- 7.12.3. Financial Overview
- 7.12.4. Product Listing
- 7.12.5. Entropy
7.13. MicroTransponder Inc.
- 7.13.1. Company Overview
- 7.13.2. Company Snapshot
- 7.13.3. Financial Overview
- 7.13.4. Product Listing
- 7.13.5. Entropy
7.14. electroCore, Inc.
- 7.14.1. Company Overview
- 7.14.2. Company Snapshot
- 7.14.3. Financial Overview
- 7.14.4. Product Listing
- 7.14.5. Entropy